Tourmaline Bio to Present at Upcoming Investor Conferences

NEW YORK, Sept. 3, 2024 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical-stage biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that CEO Sandeep Kulkarni is expected to participate in the following investor conferences:

HC Wainwright 26^and Annual Global Investor Conference, New York
Chatting by the fire
Monday, September 9, 2024 at 12:00 PM ET